Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Global Development, Inc.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject has a BMI ≤ 40.
Subject has all of the following:
1. Established diagnosis of diabetes (Type I or II) with painful diabetic peripheral neuropathy and glycosylated hemoglobin (HgbA1c) ≤ 9.5% at Screening or Randomization.
2. Stable diabetic drug regimen for at least 3 months prior to Screening.
3. At least a 1 year history of PDPN.
4. Diagnosis of PDPN to be confirmed by a score of ≥ 3 on the Michigan Neuropathy Screening Instrument (MNSI) at Screening.
Subject has pain intensity score(s) ≥ 4 or ≤ 9 on an 11-point numeric pain rating scale (NPRS) at Screening Visit and prior to Randomization.
Subject agrees to complete pain diaries and is complaint with the daily pain recording prior to Randomization as defined by the completion of a minimum of 5 of 7 daily pain ratings, 3 of which are required in the last 4 days.
Subject's anti-diabetic regimen is anticipated to be stable throughout the study.
Subject must be willing to washout of all medications currently being taken for his/her PDPN (chronic and occasional/as needed) and remain off of those pain medications while participating in the study.
You may not be if
Subject has received prior treatment with pregabalin for PDPN and was considered unresponsive or intolerant.
Subject has tried and failed 3 or more drugs to treat PDPN within the past 3 years. Drugs must have been administered at therapeutic doses and have been administered for an adequate period of time.
Subject has a known hypersensitivity to ASP3662, pregabalin, gabapentin or acetaminophen, or their formulation components.
Subject has significant pain (moderate or above) due to causes other than PDPN.
Subject has a history of painful peripheral neuropathy due to a cause other than diabetes.
Subject has any lower extremity amputation
Subject has a current or previous foot ulcer within the past 3 months as described by medical history and/or medical examination.
Subject has an active malignancy or a history of malignancy (except for treated non-melanoma skin cancer) within 5 years.
Subject has clinically significant abnormalities in clinical chemistry, hematology, or urinalysis, or a serum creatinine at Screening.
Subject has creatinine clearance \< 60 mL/min (estimated from serum creatinine, body weight, age, and sex using the Cockcroft and Gault equation) at Screening.
Subject tests positive for hepatitis B surface antigen (HBsAg) or hepatitis C antibody at Screening or has a known history of a positive test for human immunodeficiency virus (HIV) infection.
Subject has a positive drug screen for alcohol or drugs of abuse at Screening and/or Randomization. Subjects who are on low doses of benzodiazepines for sleep with a legitimate prescription will be allowed into the study. In addition, subjects with a positive drug screen at Randomization will be excluded.
Subject is currently using protocol specified non-permitted medications including OTC products and is unable or does not choose to discontinue them.
Subject has planned an elective surgery during planned study participation.
